in patients resistant to vad , high-dose therapies with intravenous melphalan , a cbv combination ( cyclophosphamide-bcnu-vp-16 ) or an edap regimen ( vp-16 -platinum ) produced responses in about 40 % of patients .
C0054917
cbv
C0010583
cyclophosphamide